Co-crystal improves the water-solubility of ASA
This could benefit patients diagnosed with suspected acute myocardial infarction
Clever crystal design improves properties
Alongside the development of new active pharmaceutical ingredients, improving the properties of established pharmaceutical products is a specialist area of research. One way to improve properties is through the clever design of crystalline substances known as co-crystals. In addition to the active ingredient, they contain molecules of other substances, so-called co-formers, which are arranged in a well-structured manner in the crystalline material. “Picture these two substances like a married couple: they’re always next to each other, but they aren’t firmly connected,” illustrates Klaus Merz. “If the co-crystal comes into contact with water, the bond dissolves and the active ingredient is released, while the excipient is degraded or excreted.”
When the water solubility of ASA is improved in this way, the active ingredient is of particular interest, because it’s used as a platelet aggregation inhibitor: It promotes blood flow and reduces the risk of thrombosis. In patients with suspected myocardial infarction, ASA is used for immediate treatment. Early administration of ASA reduces mortality by a quarter. “The substance patented here, which contains the active ingredient ASA, is significantly more water-soluble than conventional drugs and ensures that the active ingredient is absorbed more quickly into the bloodstream and can consequently take effect more quickly,” highlights Klaus Merz.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.